Navigation Links
MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
Date:1/23/2009

SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing critical strategic insight for companies developing therapies to treat hematologic malignancies. These reports are based on primary interviews conducted with hematology experts from North America immediately following the American Society of Hematology (ASH) annual meeting.

The first report, entitled "Thought Leader Insight & Analysis - AML/MDS," focuses on acute myelogenous leukemia and myelodysplastic syndrome. "This report highlights the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key emphasis of this report is transplant, and how pharmaceuticals and biologicals better prepare patients for transplant. Our thought leader panel discusses how to achieve complete responses, how they are thinking about combination therapy, and new ways for attacking quiescent malignant stem cells."

The second report, entitled "Thought Leader Insight & Analysis - Multiple Myeloma/Lymphoma," focuses on how the clinical data presented at ASH is likely to translate into changing treatment paradigms. "This report brings together the diverse perspectives of experts who grapple with a wide spectrum of issues related to these hematologic malignancies, including clinical pathology, community based patients, tertiary care treatment, and medical oncology from the strategic vantage point of clinical commercial development," said Berk.

Topics this report addresses include:

    -- Reimbursement: oral vs. parenteral; induction vs. maintenance.

    -- Multiple myeloma/lymphoma treatment strategies, including:

         - transplant eligible/non-transplant eligible;
         - induction/maintenance;
         - doublets/triplets;
         - community/tertiary care;
         - +65 years old/younger; and
         - approval pathways.

Companies mentioned in these reports include: Allos, Amgen, Bayer-Schering, Biogen Idec, BMS (Kosan), Celgene, Cell Therapeutics, Cephalon, Eisai, Genentech, Genmab, Genzyme, Geron, GSK, Gloucester, ImmunoGen, Incyte, Keryx, Mayo Scottsdale, Merck, Nereus, Novartis, PDL Biopharma, Proteolix, Rigel, Roche, Seattle Genetics, Takeda/Millennium, Vion, Wyeth, Xencor.

This report can be purchased by contacting MedPredict (www.medpredict.com).

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. Media Alert: PricewaterhouseCoopers Publishes Brief on the Impact of Government Health Reform on U.S. Employers
3. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
4. Zebrafish Journal Publishes Skin Pigmentation Studies That Shed Light on the Evolution of Race
5. HealthInsuranceFinders.com Publishes Health Insurance Guide for the Recently Unemployed
6. Dynamics Group AG Publishes Research Report on Senetek
7. PharmacyChecker.com Publishes Safe Strategies for Drug Savings to Help All Americans Get Affordable Medication
8. AMA Journal Publishes Study Showing Evidence of a Major Environmental Trigger For Autism
9. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
10. Journal of Cardiovascular Electrophysiology Publishes Data Showing Ranolazine Shortened QT Interval and Improved Cardiac Relaxation in Study of Patients With Long QT Syndrome
11. The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... DESCO ... acquired Pocono Sterilizer, an equipment sterilization service and sales company located in Pennsylvania. ... medical and research-related equipment and asset management services to the medical and academic ...
(Date:5/4/2016)... Santa Clara, California (PRWEB) , ... May 04, ... ... (ICOCD-2016) organized by United Scientific Group is scheduled on July 25-27, 2016 at ... students and other health care professionals from educational institutes and research organizations across ...
(Date:5/3/2016)... Minnesota (PRWEB) , ... May 04, 2016 , ... ... more than 40 national and global construction firms representing the Construction Industry Safety ... have joined forces with one purpose: to inspire everyone in the industry to ...
(Date:5/3/2016)... ... ... ProIntro Glitch is a set of 30 self-animating glitch-themed intros created exclusively ... add a terrifying opener to any video or media. Choose from unique styles with ... contrast, all the user has to do is increase the turn on background animations, ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... its 2016 Champion Award to Charles D. Pulido, R.Ph., Co-Founder of NCPDP and ... M.S., Ph.D., Pharmacy Advisor and Health IT Specialist, Office of the National Coordinator ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech Fund ...
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
(Date:5/3/2016)... 3, 2016 Intec Pharma Ltd. ... biopharmaceutical company, today announced the appointment of Pnina ... "Ms. Strauss-Levy has 15 years of experience ... an outstanding track record, having supported the advancement of ... processes in the United States ...
Breaking Medicine Technology: